[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Mysorekar VV, Harish K, Kilara N, Subramanian M, Giridhar AG: Embryonal rhabdomyosarcoma of the chest wall: a case report and review of the literature. Indian J Pathol Microbiol; 2008 Apr-Jun;51(2):274-6
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma of the chest wall: a case report and review of the literature.
  • Embryonal rhabdomyosarcoma is a soft-tissue sarcoma which has a predilection for the head and neck area, genitourinary tract and the extremities.
  • We report a rare case of embryonal rhabdomyosarcoma of the chest wall in an 8-year-old girl, presenting as a destructive tumor in the rib and clinically and radiologically mimicking Ewing's sarcoma.
  • Immunohistochemically, the positivity for muscle markers desmin and myogenin in the tumor cells proved to be useful for making a definitive diagnosis of embryonal rhabdomyosarcoma.
  • The patient is responding well to chemotherapy.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / diagnosis. Thoracic Neoplasms / diagnosis. Thoracic Wall / pathology
  • [MeSH-minor] Aneuploidy. Child. Diagnosis, Differential. Female. Humans. Sarcoma, Ewing / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603708.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 9
  •  go-up   go-down


2. Loeb DM, Thornton K, Shokek O: Pediatric soft tissue sarcomas. Surg Clin North Am; 2008 Jun;88(3):615-27, vii

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric soft tissue sarcomas.
  • Soft tissue sarcomas in children are rare.
  • Approximately 850 to 900 children and adolescents are diagnosed each year with rhabdomyosarcoma (RMS) or a non-RMS soft tissue sarcoma (NRSTS).
  • Surgery is a major therapeutic modality and radiation plays a role.
  • RMS is treated with adjuvant chemotherapy, whereas chemotherapy is reserved for the NRSTS that are high grade or unresectable.
  • This review discusses the etiology, biology, and treatment of pediatric soft tissue sarcomas.
  • [MeSH-major] Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Child. Humans. Neoplasm Staging. Radiotherapy Dosage. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma, Embryonal / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514702.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  • [Other-IDs] NLM/ NIHMS646294; NLM/ PMC4273573
  •  go-up   go-down


3. Basu S, Baghel NS, Puri A, Shet T, Merchant NH: 18 F-FDG avid lesion due to coexistent fibrous dysplasia in a child of embryonal rhabdomyosarcoma: source of false positive FDG-PET. J Cancer Res Ther; 2010 Jan-Mar;6(1):92-4
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18 F-FDG avid lesion due to coexistent fibrous dysplasia in a child of embryonal rhabdomyosarcoma: source of false positive FDG-PET.
  • With increasing use of 18 F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in the current oncological practice, there is a growing body of evidence of false positive scans due to various benign conditions.
  • In this communication we present intensely avid 18 F-FDG uptake in fibrous dysplasia of right tibia in a 12-year-old child suffering from embryonal rhabdomyosarcoma (ERMS) that could have been easily mistaken to be a metastatic focus if not carefully correlated.
  • The patient was a case of ERMS (presenting with left cervical mass with intrathoracic extension) who was treated successfully with chemotherapy and was referred for FDG-PET to evaluate the disease status.
  • The computed tomography (CT) scan of the same region showed cortical thickening and increased density within the medullary cavity in the shaft of the tibia.
  • A histopathological diagnosis was sought for and the lesion was subsequently proven to be fibrous dysplasia by histopathology of the bone piece obtained from the right tibial lesion by J needle biopsy.
  • [MeSH-major] Fibrous Dysplasia of Bone / radionuclide imaging. Fluorodeoxyglucose F18. Radiopharmaceuticals. Rhabdomyosarcoma, Embryonal / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging
  • [MeSH-minor] Child. False Positive Reactions. Humans. Male. Neoplasm Metastasis / pathology. Positron-Emission Tomography. Tibia / pathology

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479556.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Durisin M, Mengel M, Beilken A, Donnerstag F, Lenarz T, Stöver T: [Embryonal rhabdomyosarcoma of the orbita]. Laryngorhinootologie; 2006 Feb;85(2):124-7
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Embryonal rhabdomyosarcoma of the orbita].
  • CT and MRT scanning revealed a tumor which by open biopsy disclosed embryonal rhabdomyosarcoma.
  • By means of this case we present the current diagnostic and therapeutic approaches for childhood soft tissue sarcomas.
  • At present our patient receives a poly-chemotherapy which has already shown a good response.
  • This case demonstrates that in a child with a unilateral, progressive orbital tumor, the differential diagnosis of a soft tissue sarcoma has to be ruled out.
  • [MeSH-major] Orbital Neoplasms. Rhabdomyosarcoma, Embryonal
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child, Preschool. Diagnosis, Differential. Exophthalmos / etiology. Female. Humans. Orbit / pathology. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498541.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Takahashi T, Machida K, Honda N, Hosono M, Kashimada A, Murata O, Osada H, Nishimura K: Adult embryonal rhabdomyosarcoma in axilla. Radiat Med; 2003 May-Jun;21(3):135-7
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult embryonal rhabdomyosarcoma in axilla.
  • A case of embryonal rhabdomyosarcoma (RMS) arising from an axillary space is described.
  • RMS is one of the most common soft-tissue neoplasms in children, but adult embryonal RMS is rare.
  • The histological diagnosis was embryonal RMS.
  • He received irradiation combined with chemotherapy (VAC: VCR, act-D, CPA) for the primary and metastatic lesions, obtained complete remission, and has remained disease-free for over four years as of this report.
  • [MeSH-major] Axilla. Rhabdomyosarcoma, Embryonal. Soft Tissue Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Male. Middle Aged. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12868862.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Cecchetto G, Bisogno G, Treuner J, Ferrari A, Mattke A, Casanova M, Dall'Igna P, Zanetti I, Volpato S, Siracusa F, Scarzello G, Boglino C, Carli M, Italian and German Soft Tissue Cooperative Groups Studies: Role of surgery for nonmetastatic abdominal rhabdomyosarcomas: a report from the Italian and German Soft Tissue Cooperative Groups Studies. Cancer; 2003 Apr 15;97(8):1974-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of surgery for nonmetastatic abdominal rhabdomyosarcomas: a report from the Italian and German Soft Tissue Cooperative Groups Studies.
  • BACKGROUND: In the current study, the authors aim to evaluate clinical features and treatment results observed in patients from the German and Italian studies who had nonmetastatic abdominal rhabdomyosarcomas (RMS).
  • The distribution of tumor sites was as follows: 32 intraperitoneal, 42 retroperitoneal, 75 pelvic, and 12 not otherwise specified (NOS).
  • The breakdown in histology was as follows: 116 embryonal, 34 alveolar, and 11 other (leiomyomatous, pleomorphic, and NOS); all cases were staged according to the Intergroup Rhabdomyosarcoma Studies (IRS) system.
  • Nine Group I patients were treated after surgery with chemotherapy (CT) (radiotherapy [RT] was delivered to treat alveolar RMS in the 1991 German and 1988 Italian studies); 19 Group II patients received CT + RT (40-44 Gy); 133 Group III patients underwent neoadjuvant CT +/- surgery and/or RT (54 Gy) + CT.
  • The OS was related significantly to the following variables: histology (alveolar, 29.4% vs. nonalveolar, 52.1% [P = 0.0156]), tumor size (> 5 cm, 42.1% vs. < 5 cm, 81% [P = 0.005]), age (< 10 yrs, 51.4% vs. >or= 10 yrs, 27.8% [P = 0.02]), complete surgery at diagnosis or after CT (+/-RT) (70.4% vs. 34.4% without it [P = 0.0015]).
  • [MeSH-major] Abdominal Neoplasms / surgery. Rhabdomyosarcoma / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12673726.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarria P, Collini P, Gronchi A, Olmi P, Fossati-Bellani F, Casali PG: Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer; 2003 Aug 1;98(3):571-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.
  • BACKGROUND: The goal of the current study was to clarify treatment outcomes for adult patients with rhabdomyosarcoma (RMS).
  • METHODS: Of 190 patients with RMS who were age 18 years or older and whose cases were recorded over a 25-year span in the pathology database of the Istituto Nazionale Tumori (Milan, Italy), 171 could be analyzed retrospectively for treatment outcome.
  • The authors attempted to stratify patients according to the degree to which they had been treated appropriately, based on current treatment guidelines for childhood RMS.
  • RESULTS: The overall rate of response to chemotherapy was 85%.
  • Among the 110 patients with embryonal, alveolar, or 'not otherwise specified' RMS, 5-year OS was 46%; however, 5-year OS was 61% for patients within this group (39% of the total) who had high scores for appropriate treatment.
  • However, for patients whose treatment adhered to the current guidelines for treatment of children, outcome was similar to what has been reported in pediatric series.
  • In addition, the rate of response to chemotherapy for the entire series was similar to the rate typically observed among children.
  • These findings suggest that adults and children with RMS should receive similar treatment.
  • Treatment protocols adopted from pediatric programs but tailored to adults could increase adults' chances of receiving appropriate treatment; prospective studies are needed to test this idea.
  • [MeSH-major] Rhabdomyosarcoma, Alveolar / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Retrospective Studies. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / mortality. Rhabdomyosarcoma, Embryonal / therapy. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11550
  • (PMID = 12879475.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


8. Ferrari A, Bisogno G, Macaluso A, Casanova M, D'Angelo P, Pierani P, Zanetti I, Alaggio R, Cecchetto G, Carli M: Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer; 2007 Apr 1;109(7):1406-12
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1.
  • BACKGROUND: Patients affected by neurofibromatosis type 1 (NF1) are at higher risk of developing soft-tissue sarcomas (STS) than the general population.
  • METHODS: The study included 37 patients with neurogenic sarcomas (36 malignant peripheral nerve sheath tumors [MPNST], 1 triton tumor) and 6 cases of rhabdomyosarcoma (RMS).
  • Two of 16 patients with evaluable disease responded to chemotherapy.
  • All 6 RMS patients were </=3 years old and had embryonal subtype, 5 of 6 arising in the genitourinary tract or pelvis (paravesical); 4 were alive in first remission at the time of the analysis, 1 was alive in second remission after a local recurrence, and 1 died of disease.
  • Cases of RMS tended to have particular features (early age, embryonal histotype, genitourinary site) and their outcome seemed to resemble that of the general RMS population.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasms, Second Primary / complications. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / therapy. Nerve Sheath Neoplasms / complications. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / therapy. Neurofibrosarcoma / complications. Neurofibrosarcoma / diagnosis. Neurofibrosarcoma / therapy. Peripheral Nervous System Neoplasms / complications. Peripheral Nervous System Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / therapy. Prognosis. Prospective Studies. Rhabdomyosarcoma / complications. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17330850.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Viswanatha B: Embryonal rhabdomyosarcoma of the temporal bone. Ear Nose Throat J; 2007 Apr;86(4):218, 220-2
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma of the temporal bone.
  • The most common soft-tissue sarcoma in infants and children is rhabdomyosarcoma.
  • Multimodality therapy--surgery, multiagent chemotherapy, and radiotherapy-yields sufficiently good results.
  • The author reports a case of embryonal rhabdomyosarcoma of the temporal bone with cranial nerve palsies and extension into the parapharyngeal space in a 4-year-old boy.
  • Despite surgery and chemotherapy, the patient died of his disease within 3 months of presentation.
  • [MeSH-major] Ear Canal. Ear Neoplasms / diagnosis. Ear, Middle. Facial Paralysis / etiology. Mastoid. Ophthalmoplegia / etiology. Rhabdomyosarcoma, Embryonal / diagnosis. Skull Neoplasms / diagnosis. Temporal Bone
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Palliative Care. Pharyngeal Neoplasms / diagnosis. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17500393.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Ruymann FB, Grovas AC: Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest; 2000;18(3):223-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.
  • Advances in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas continue in the Intergroup Rhabdomyosarcoma Study Group (IRSG) and European cooperative groups.
  • The use of molecular biology techniques in soft tissue sarcomas are redefining the classic pathology of these small blue cell tumors.
  • These advances confound the interpretation of consecutively run chemotherapy trials using historical comparisons.
  • The IRSG has reported improvement in the prognosis of both nonmetastatic and metastatic embryonal rhabdomyosarcoma as attributable to three, three-drug regimens that use cyclophosphamide at 2.2 g/m2 in either maintenance or induction and maintenance therapy.
  • Patients of any age with metastatic, nonembryonal, and those over 10 years of age with metastatic embryonal rhabdomyosarcoma continue to have a poor prognosis, which even megatherapy has failed to change.
  • The doublet of ifosfamide and etoposide in combination with vincristine, actinomycin D, and cyclophosphamide at 2.2 g/m2 achieved a remarkable 3-year survival of 58% in patients with metastatic rhabdomyosarcoma and undifferentiated soft tissue sarcoma.
  • The topoisomerase I inhibitor, topotecan, has recently been found by the IRSG to have a 57% overall response rate in patients with metastatic alveolar rhabdomyosarcoma.
  • Molecular studies in IRSG-V will be applied in the detection of occult bone marrow metastases and the evaluation of resection margins at initial and second-look surgery.
  • Although older patients with unfavorable histology and metastatic disease continue to have a poor prognosis, the overall 5-year survival of children and adolescents with nonmetastatic and metastatic rhabdomyosarcoma is approaching 80%.
  • As molecular discoveries advance the diagnosis and detection of rhabdomyosarcoma, it is hoped that the futuristic molecular based treatment strategies in development and early testing will further improve survival in high-risk patients with metastatic soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Sarcoma / diagnosis. Sarcoma / therapy. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10754991.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16058; United States / NCI NIH HHS / CA / U10 CA03750-39; United States / NCI NIH HHS / CA / U10 CA24507-17
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 121
  •  go-up   go-down


11. Hardaway CA, Graham BS, Barnette DJ, Feldman BD: Embryonal rhabdomyosarcoma presenting in an adult: a case report and discussion of immunohistochemical staining. Am J Dermatopathol; 2003 Feb;25(1):45-52
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma presenting in an adult: a case report and discussion of immunohistochemical staining.
  • Embryonal rhabdomyosarcoma is the most common soft tissue sarcoma of childhood but is rarely seen in adults.
  • We report an embryonal rhabdomyosarcoma of the cheek in a 21-year-old Filipino man presenting as a rapidly enlarging mass.
  • An incisional biopsy was consistent with embryonal rhabdomyosarcoma.
  • The patient failed to respond to one cycle of chemotherapy after initial diagnosis and workup for metastatic disease.
  • The patient subsequently underwent radiation therapy for a total of 6,000 cGy, followed by two cycles of chemotherapy.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Etoposide / therapeutic use. Humans. Ifosfamide / therapeutic use. Immunohistochemistry. Male. Neoplasm Proteins / chemistry. Radiotherapy, Adjuvant. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12544100.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Hessissen L, Kanouni L, Kili A, Nachef MN, El Khorassani M, Benjaafar N, Khattab M, El Gueddari Bel K: Pediatric rhabdomyosarcoma in Morocco. Pediatr Blood Cancer; 2010 Jan;54(1):25-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric rhabdomyosarcoma in Morocco.
  • BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the first two decades of life.
  • The male/female ratio was 2:1 with a mean age at diagnosis of 5 years.
  • The embryonal subtype was the most frequent (73%) and the head and neck was the most common site of disease, followed by the genito-urinary tract and limbs.
  • Chemotherapy was used in all patients; 44% also had a radical surgery and 23% radiation therapy.
  • The event-free survival (EFS) at 10 years was 39% with relapse as the first cause of treatment failure.
  • The rate of treatment abandonment was 37%.
  • However, EFS is lower than that reported elsewhere due to occasional lack of availability of drugs, inadequate local control, and abandonment.
  • [MeSH-major] Rhabdomyosarcoma / epidemiology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Morocco / epidemiology. Neoplasm Staging. Prognosis. Radiotherapy. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19746454.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Nicol K, Savell V, Moore J, Teot L, Spunt SL, Qualman S, Children's Oncology Group, Soft Tissue Sarcoma Committee: Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma: a Children's Oncology Group study. Pediatr Dev Pathol; 2007 Mar-Apr;10(2):89-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma: a Children's Oncology Group study.
  • Morphologically, the distinction between undifferentiated embryonal sarcoma of the liver (UESL) and biliary tract rhabdomyosarcoma (RMS) can be uncertain because of some shared pathologic similarities.
  • Patients with UESL have been consistently but erroneously enrolled in Children's Oncology Group (COG) treatment protocols because UESL was equated with RMS, despite the differing primary treatment modalities of these entities.
  • Establishing the correct diagnosis of these distinct clinical and pathologic entities is important, as surgery alone may be curative in UESL, whereas initial chemotherapy is often recommended for the treatment of biliary tract RMS.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Biomarkers, Tumor / analysis. Liver Neoplasms / diagnosis. Rhabdomyosarcoma / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Child. Child, Preschool. Diagnosis, Differential. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. MyoD Protein / metabolism. Myogenin / metabolism. Neoplasm Proteins / metabolism. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome


14. Stevens M, Rey A, Bouvet N, Ellershaw C, Sanchez de Toledo J, Oberlin O: SIOP MMT 95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS). J Clin Oncol; 2004 Jul 15;22(14_suppl):8515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIOP MMT 95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS).
  • Principal study objectives were: low and standard risk patients, to maintain excellent survival with limited chemotherapy and very selective use of local therapy.
  • ; high risk patients, to explore survival advantage for an intensified chemotherapy strategy in a randomised trial.
  • METHODS: Eligibility for randomisation included age ≥ 6 months ≤18 years, no distant metastases, diagnosis within previous 8 weeks without prior treatment except surgery, pathology available for central review, written consent according to institutional requirement.
  • From July 1995 to July 2003, 456 high risk patients (incompletely resected embryonal RMS, undifferentiated sarcoma and soft tissue PNET at all sites except paratesticular, vagina and uterus, and all alveolar RMS) were randomised to receive IVA (ifosfamide, vincristine, actinomycin D) or a 6 drug combination (IVA + carboplatin, epirubicin, etoposide) both delivered over 27 weeks.
  • Cumulative dose / m<sup>2</sup> = ifosfamide 54g (both arms), epirubicin 450 mg, etoposide 1350 mg (6 drug).
  • Delivery of radiotherapy was determined according to site and / or response to chemotherapy ± surgery.
  • Non randomised exceptions were: orbital tumours (allocated IVA); SIOP stage III (node positive) and young (age < 3yr) parameningeal tumours (allocated 6 drugs).
  • RESULTS: Data given only for randomised patients [Figure: see text] Toxicity was significantly greater (infection, myelosuppression, mucositis) for the 6 drug arm.
  • CONCLUSIONS: Intensification of chemotherapy provides no overall advantage for non metastatic RMS / other chemosensitive STS, and adds toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013776.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Cribbs RK, Shehata BM, Ricketts RR: Primary ovarian rhabdomyosarcoma in children. Pediatr Surg Int; 2008 May;24(5):593-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian rhabdomyosarcoma in children.
  • Although rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, primary rhabdomyosarcomas of the ovary are extremely rare, with only eight well-documented pediatric cases previously reported in the literature.
  • We present two additional cases: an alveolar RMS originating in the right ovary with metastatic spread to the splenic flexure of the colon and to both lungs in a 13-year-old African American girl, and an embryonal RMS arising in the right ovary of a 6-year-old Caucasian girl with pre-operative intra-abdominal rupture and a malignant right pleural effusion.
  • Both patients had complete resection of their primary tumors and received chemotherapy including vincristine, doxorubicin and cyclophosphamide with good response to therapy.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Rhabdomyosarcoma / diagnosis
  • [MeSH-minor] Adolescent. Biopsy, Needle. Chemotherapy, Adjuvant. Child. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laparoscopy. Ovariectomy / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] AMA Arch Pathol. 1959 Jul;68(1):74-82 [13660587.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17(2):113-9 [9553806.001]
  • [Cites] J Pathol Bacteriol. 1955 Oct;70(2):433-8 [13295919.001]
  • [Cites] Histopathology. 1989 Sep;15(3):309-11 [2807189.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):297-300 [6574802.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):899-904 [2545329.001]
  • [Cites] Gynecol Oncol. 1983 Jun;15(3):325-39 [6345285.001]
  • (PMID = 18004572.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Ayadi L, Chaabouni S, Chabchoub I, Ayadi A, Kallel R, Fakhfakh I, Hachicha M, Boudawara T: [Primary rhabdomyosarcoma of the pleura presenting as recurrent pneumothorax]. Rev Mal Respir; 2009 Mar;26(3):333-7
MedlinePlus Health Information. consumer health - Collapsed Lung.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary rhabdomyosarcoma of the pleura presenting as recurrent pneumothorax].
  • INTRODUCTION: Rhabdomyosarcoma is the most common soft tissue sarcoma in the first two decades of life.
  • We report a case of primary pleural rhabdomyosarcoma with an unusual clinical presentation and location.
  • Our aim is to discuss the clinical presentation, treatment and prognosis of this uncommon location of rhabdomyosarcoma.
  • CASE REPORT: We report a case of primary embryonal rhabdomyosarcoma of the pleura in a boy of 21 months.
  • A computed tomography scan showed only pleural detachment with no evidence of any pleural disease.
  • Despite chemotherapy, the tumour quickly increased in size and the infant died from acute respiratory failure.
  • CONCLUSION: Thoracic rhabdomyosarcoma is rare and remains clinically silent for a long time.
  • [MeSH-major] Pleural Neoplasms / diagnosis. Pneumothorax / etiology. Rhabdomyosarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367209.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


17. Huh WW, Skapek SX: Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep; 2010 Nov;12(6):402-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood rhabdomyosarcoma: new insight on biology and treatment.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood.
  • The two most common histologic variants are the embryonal and alveolar subtypes.
  • Other studies have implicated several cellular mechanisms and pathways being involved in RMS pathogenesis and survival, such as the cyclin-dependent kinase inhibitors, insulin-like growth factor pathway, and the mammalian target of rapamycin pathway, thus providing potential avenues for targeted therapy.
  • Recent clinical trials have tried to improve risk stratification and prediction of clinical outcome based upon clinical or radiographic response to initial therapy and also to determine the role of high-dose chemotherapy with stem cell rescue in high-risk RMS patients.
  • [MeSH-major] Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / therapy. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / genetics. Rhabdomyosarcoma, Embryonal / therapy. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Mesenchymal Stromal Cells / pathology. Mice. Neoplasm Metastasis. Neoplasm Staging. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Prognosis. Protein Kinase Inhibitors / administration & dosage. Risk Factors. Secondary Prevention. Signal Transduction / drug effects. Signal Transduction / genetics. Sirolimus / administration & dosage. Survival Rate. TOR Serine-Threonine Kinases / antagonists & inhibitors. Tomography

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2009 Sep 15;115(18):4218-26 [19536876.001]
  • [Cites] J Clin Invest. 2009 Nov;119(11):3395-407 [19809159.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1322-8 [20124176.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2384-9 [18467730.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):348-58 [17243166.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):466-71 [15386014.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Pediatr Dev Pathol. 2009 Mar-Apr;12 (2):127-35 [18788888.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jun;48(6):455-67 [19235922.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1271-6 [19293315.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4909-13 [17971587.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(17):3035-41 [19783136.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3242-7 [18985676.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5435-41 [18048826.001]
  • [Cites] Stem Cells. 2008 Jul;26(7):1818-30 [18467664.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14 ):6936-46 [16849537.001]
  • [Cites] Genes Chromosomes Cancer. 2010 Mar;49(3):224-36 [19953635.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] J Clin Oncol. 2010 Mar 1;28(7):1240-6 [20124188.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6587-97 [18701482.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):327-32 [12865925.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Nov;48(11):975-82 [19681119.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7662-71 [19789339.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13439-44 [16938866.001]
  • [Cites] Cell. 2000 Dec 22;103(7):1099-109 [11163185.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):739-45 [18286501.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3431-40 [17409454.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):799-805 [17635004.001]
  • [Cites] Cancer Lett. 2009 Jul 8;279(2):126-36 [19008039.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1446-55 [19224858.001]
  • [Cites] J Pediatr. 2004 May;144(5):666-8 [15127010.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5182-8 [19770373.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Aug;48(8):661-72 [19422036.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):161-70 [19117999.001]
  • [Cites] Br J Cancer. 2010 Jan 5;102(1):227-31 [19997102.001]
  • [Cites] J Clin Oncol. 2010 May 1;28(13):2151-8 [20351326.001]
  • [Cites] Cell. 2005 Sep 9;122(5):659-67 [16143100.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):550-64 [19147825.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Sep;29(9):608-12 [17805034.001]
  • [Cites] Eur J Cancer. 2010 Jun;46(9):1588-95 [20338746.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3705-11 [19470937.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1276-80 [12368906.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(2):179-80 [18762761.001]
  • [Cites] Future Oncol. 2009 Nov;5(9):1449-75 [19903072.001]
  • (PMID = 20820958.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


18. Sbeity S, Abella A, Arcand P, Quintal MC, Saliba I: Temporal bone rhabdomyosarcoma in children. Int J Pediatr Otorhinolaryngol; 2007 May;71(5):807-14
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal bone rhabdomyosarcoma in children.
  • OBJECTIVE: Rhabdomyosarcoma is the most frequent soft tissue sarcoma in the pediatric age group.
  • The authors present their series of rhabdomyosarcoma of the temporal bone in children at Saint Justine Hospital.
  • METHODS: A retrospective study was conducted of patients diagnosed and treated for rhabdomyosarcoma of the head and neck at Saint Justine Hospital, a tertiary pediatric center, between 1970 and 2005.
  • Only cases of temporal bone rhabdomyosarcoma were included in the study.
  • A thorough review of medical and surgical charts was performed to obtain demographic, clinical, paraclinical, and therapeutic data, which were subsequently analyzed and compared to published results.
  • A MEDLINE search yielded 34 studies dealing with temporal bone rhabdomyosarcoma since the year 1966.
  • RESULTS: Thirty-nine patients with rhabdomyosarcoma of the head and neck region were identified, among which only six children had temporal bone rhabdomyosarcoma.
  • The mean age at the time of diagnosis was 4.15 years.
  • Five children had the embryonal subtype and one had the botryoid subtype on histology.
  • All patients except two received combined chemotherapy and radiotherapy as treatment.
  • CONCLUSION: Rhabdomyosarcoma of the temporal bone is an aggressive tumor that clinically simulates chronic otitis media.
  • A high index of suspicion should be raised in the context of otitis media that is unresponsive to ordinary medical treatment.
  • A biopsy is hence recommended in the presence of polyps in the external auditory canal that are resistant to medical treatment.
  • Early diagnosis and the adoption of multimodal therapy offer the best outcome.
  • [MeSH-major] Bone Neoplasms / pathology. Rhabdomyosarcoma / pathology. Temporal Bone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346806.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


19. Sinha R, Bandyopadhyay SN, Pathak K, Hati G: Rhabdomyosarcoma of nose and paranasal sinuses--a therapeutic challenge. J Indian Med Assoc; 2006 Sep;104(9):519-21
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of nose and paranasal sinuses--a therapeutic challenge.
  • Rhabdomyosarcoma is a highly malignant tumour of striated muscle and it is the most common soft tissue sarcoma in the paediatric age group.
  • Histologically embryonal rhabdomyosarcoma is the most common variant.
  • The present series deals with seven such cases of different histopathological types including the embryonal, botryoid, and alveolar varieties in the paediatric age group.
  • Multimodal treatment including limited surgery followed by radiotherapy and chemotherapy resulted in survival ranging from 3 days to more than 3 years, which was also influenced by the severity of the disease at presentation and its aggressiveness.
  • [MeSH-major] Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Biopsy. Child. Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. India / epidemiology. Male. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388011.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] India
  •  go-up   go-down


20. Mentzel T, Kuhnen C: Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases. Virchows Arch; 2006 Nov;449(5):554-60
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases.
  • Rhabdomyosarcoma (RMS) is currently classified into embryonal RMS, including its botryoid and spindle cell variants, alveolar RMS, including a solid variant, and pleomorphic RMS.
  • In children and adolescents embryonal RMS occurs in a younger age group than alveolar RMS, and pleomorphic RMS is almost always seen in older adults.
  • Five neoplasms were completely excised, in one incompletely excised neoplasm additional chemotherapy was given, and in one patient a biopsy was done only so far.
  • All neoplasms arose in subcutaneous and deep soft tissues with dermal involvement in one case, and the size of the neoplasms ranged from 4 to 19 cm in largest diameter.
  • In summary, spindle cell rhabdomyosarcoma represents a rare neoplasm in adulthood characterized clinically by a rather poor prognosis, and shows a broad morphological spectrum including most likely the sclerosing, pseudovascular variant.
  • Immunohistochemically, tumour cells in RMS stain positively for CD 99 and WT1 as well, which is of importance in the differential diagnosis to other mesenchymal neoplasms, whereas fast myosin does not represent a reliable marker for RMS in adults.
  • [MeSH-major] Rhabdomyosarcoma / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Aug 1;98(3):571-80 [12879475.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):572-8 [17016719.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):399-408 [10666368.001]
  • [Cites] Pediatr Dev Pathol. 2004 Nov-Dec;7(6):583-94 [15630526.001]
  • [Cites] Virchows Arch. 2000 Apr;436(4):305-11 [10834531.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):221-30 [8434703.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):595-603 [11406662.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):215-23 [11505068.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):794-803 [11241248.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):229-35 [1599014.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1106-13 [16006807.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1080-6 [12379755.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):64-7 [15660283.001]
  • (PMID = 17013628.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD99; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


21. Raney RB, Anderson JR, Andrassy RJ, Crist WM, Donaldson SS, Maurer HM, Intergroup Rhabdomyosarcoma Study Group: Soft-tissue sarcomas of the diaphragm: a report from the Intergroup Rhabdomyosarcoma Study Group from 1972 to 1997. J Pediatr Hematol Oncol; 2000 Nov-Dec;22(6):510-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas of the diaphragm: a report from the Intergroup Rhabdomyosarcoma Study Group from 1972 to 1997.
  • PURPOSE: To describe clinical details and outcome of children and adolescents with primary sarcomas of the diaphragm treated on Intergroup Rhabdomyosarcoma Studies (IRS) I through IV.
  • Patient ages at diagnosis ranged from 0.5 to 20 years (median, 13 yrs), and 10 were girls.
  • RESULTS: Localized, gross residual disease after initial surgery was present in 10 patients, and five had metastases at diagnosis (pleura, 3; pericardium, 1; lungs and bones, 1).
  • Tumor subtypes were alveolar rhabdomyosarcoma (RMS) in five cases, embryonal RMS in three, undifferentiated sarcoma in three, extraosseous Ewing sarcoma in three, and unclassified sarcoma in one.
  • Treatment consisted of radiation therapy to the primary tumor and metastases when feasible, and combination chemotherapy with vincristine, actinomycin D, and cyclophosphamide with or without doxorubicin, ifosfamide, cisplatin, and etoposide.
  • Five patients (33%) are continuously failure-free and alive at a median of 8.8 years from diagnosis (range, 1.1-15 yrs).
  • However, the other 10 patients experienced relapse at 0.3 to 2 years from start of therapy (median, 1 yr).
  • Death after relapse occurred at 0.39 to 2.6 years (median, 1.6 yrs) from diagnosis.
  • CONCLUSIONS: Sarcomas of the diaphragm are generally deemed unresectable at diagnosis and/or are metastatic.
  • Most of them are not embryonal rhabdomyosarcomas.
  • Treatment with more effective primary chemotherapy to shrink the tumor, followed-up by surgical resection and radiation therapy, should improve the prognosis for patients with sarcomas arising in the diaphragm, especially for the majority who have localized tumors.
  • [MeSH-major] Muscle Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Diaphragm. Female. Humans. Infant. Male. Radiotherapy Dosage. Recurrence. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11132218.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989
  • [Publication-type] Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


22. Pappo AS, Meza JL, Donaldson SS, Wharam MD, Wiener ES, Qualman SJ, Maurer HM, Crist WM: Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV. J Clin Oncol; 2003 Feb 15;21(4):638-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV.
  • PURPOSE: The characteristics and clinical outcomes of children and adolescents with localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma (RMS) treated on national protocols from the Intergroup Rhabdomyosarcoma Group are reported.
  • PATIENTS AND METHODS: We conducted a retrospective review of 164 children and adolescents enrolled in the third and fourth Intergroup Rhabdomyosarcoma Studies.
  • Variables analyzed included age, sex, primary tumor site, histologic subtype, clinical group, therapy, site and rate of treatment failure, and time to initial recurrence.
  • The median age at diagnosis was 5 years; the median follow-up was 6.6 years.
  • For patients with embryonal tumors, FFS was significantly improved, especially among patients with Group I/II without nodal disease clinical Group I, II N0.
  • Our results indicate that early, limited exposure to cyclophosphamide might reduce recurrence in low-risk embryonal patients and that reduced dosages might achieve comparable results with improved toxicity profiles.
  • These hypotheses will be tested in the next generation of trials from the Soft Tissue Committee of the Children's Oncology Group.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Disease-Free Survival. Head and Neck Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12586800.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 24507; United States / NCI NIH HHS / CA / CA 72989
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Solomon LA, Zurawin RK, Edwards CL: Vaginoscopic resection for rhabdomyosarcoma of the vagina: a case report and review of the literature. J Pediatr Adolesc Gynecol; 2003 Jun;16(3):139-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginoscopic resection for rhabdomyosarcoma of the vagina: a case report and review of the literature.
  • Rhabdomyosarcoma is the most common soft-tissue sarcoma found in children.
  • A polypoid form of the embryonal type of rhabdomyosarcoma, sarcoma botyroides, is often found in girls under age 5.
  • Their superficial location and clinical symptoms lead to early diagnosis, and these tumors are therefore considered to be the easiest to treat and most likely to be cured.
  • In the past 30 years we have seen a shift in treatment from radical surgery to conservative surgery with chemotherapy and radiation, with improved survival and preservation of normal anatomy and improved postoperative body imagery.
  • [MeSH-major] Rhabdomyosarcoma / diagnosis. Vaginal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12804937.001).
  • [ISSN] 1083-3188
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


24. Kazanowska B, Mikołajewska A, Balcerska A, Balwierz W, Bodalski J, Dłuzniewska A, Drozyńska E, Kurylak A, Reich A, Stencel D, Szewczyk B, Wachowiak J, Wysocki M, Chybicka A: [Soft tissue sarcoma of the bladder and prostate. A report of the Polish Paediatric Solid Tumour Group (PPSTG)]. Med Wieku Rozwoj; 2004 Oct-Dec;8(4 Pt 2):1091-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcoma of the bladder and prostate. A report of the Polish Paediatric Solid Tumour Group (PPSTG)].
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children younger then 15 years of age.
  • The treatment of RMS localized in bladder or prostate still remains controversial.
  • The aim of this study was analysis of treatment results in children with soft tissue sarcoma of bladder and prostate.
  • From 1993 to 2001 the PPSTG has used three protocols to treat soft tissue sarcomas in children.
  • After biopsy confirmation of the diagnosis patients were treated with chemotherapy and subsequent surgery.
  • The median follow-up time was 42 months.
  • RMS-embryonal was diagnosed in 11 patients, RMS-alveolare in 4 and others types in 4.
  • After induction chemotherapy two patients received partial cystectomy, 5 complete cystectomy and 3 complete cystectomy with genitourinary reconstructive.
  • The most common treatment failure was isolated, local relapse in 8 children particularly in patients with any second surgery.
  • Significant prognostic factors are the initial tumours volume, the lymph nodes infiltration and the response to the first chemotherapy cycle.
  • Surgery is the most important procedure in local control of soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms. Rhabdomyosarcoma. Urinary Bladder Neoplasms
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Cystectomy / methods. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Poland. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951604.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


25. Chigurupati R, Alfatooni A, Myall RW, Hawkins D, Oda D: Orofacial rhabdomyosarcoma in neonates and young children: a review of literature and management of four cases. Oral Oncol; 2002 Jul;38(5):508-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orofacial rhabdomyosarcoma in neonates and young children: a review of literature and management of four cases.
  • Rhabdomyosarcoma (RMS) is an aggressive malignant skeletal muscle neoplasm arising from embryonal mesenchyme.
  • It accounts for over 50% of all pediatric soft tissue sarcomas.
  • Three of the four cases were alveolar RMS and one was botryoid sub-type of embryonal RMS.
  • Three patients were treated with a combination of surgery, chemotherapy and radiation, while the patient with botryoid RMS was treated with surgery and chemotherapy only.
  • We discuss the current management, diagnosis, biological behavior, histopathology, prognosis and survival of head and neck RMS in neonates and young children.
  • [MeSH-major] Facial Neoplasms / therapy. Mouth Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Fatal Outcome. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12110348.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


26. Antillon F, Castellanos M, Valverde P, Luna-Fineman S, Garrido C, Serrato T, Rodriguez-Galindo C, Casanova M, Ferrari A: Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatr Blood Cancer; 2008 Dec;51(6):760-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala.
  • BACKGROUND: About 250-300 children with newly diagnosed cancer are treated each year at the Unidad Nacional de Oncologia Pediatrica in Guatemala City; less than 5% of them have soft tissue sarcomas (STS).
  • The aim of the article was to evaluate whether the therapeutic standards achieved in STS in developed countries could be reproduced in a low-income country.
  • PATIENTS AND METHODS: We reviewed the clinical data, treatment and outcome of 80 patients, 47 cases of rhabdomyosarcoma (RMS) and 33 of non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), treated between January 2000 and October 2007.
  • RESULTS: Most of the RMS patients had advanced disease at diagnosis (87% groups III-IV).
  • Their 3-year event-free survival rate (EFS) was 26.4% if abandoning the treatment was considered as an event, or 32.4% if it was censored (14 patients abandoned the treatment), and the 3-year overall survival rate (OS) was 43.5%.
  • Local progression/relapse was the main cause of treatment failure.
  • Among the patients with NRSTS, the EFS at 3 years was 36.4% (when abandoning the treatment was considered as an event) or 43.3% (when it was censored), and the OS was 44.2%.
  • CONCLUSIONS: Overall results were unsatisfactory compared to results reported from developed countries.
  • Late diagnosis and the consequently high proportion of cases of advanced disease at diagnosis, the large number of patients failing to complete the treatment, and the poor quality of local control (in RMS) adversely influence outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Developing Countries. Rhabdomyosarcoma, Alveolar / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Guatemala. Humans. Infant. Male. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18680154.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Paner GP, McKenney JK, Epstein JI, Amin MB: Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma. Am J Surg Pathol; 2008 Jul;32(7):1022-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma.
  • Rhabdomyosarcoma (RMS) represents the most common malignant soft tissue tumor in children and adolescents with the urinary bladder representing a frequent site.
  • Most of these urinary bladder tumors are embryonal RMS, predominantly the botryoid subtype.
  • We report the clinicopathologic features of 5 bladder neoplasms with rhabdomyosarcomatous differentiation in adults and emphasize the differential diagnosis in the adult setting.
  • Three cases were of the alveolar subtype (1 admixed with embryonal histology) and 2 were RMS, not further classified.
  • Two patients received chemotherapy, 2 underwent cystectomy, and 1 had transurethral resection alone.
  • In conclusion, (1) RMS of the urinary bladder in adults more commonly presents as a primitive round blue cell neoplasm that has significant morphologic and immunohistochemical overlap with small cell carcinoma of the bladder. (2) Although RMS in children generally have a botryoid embryonal histology with favorable outcome, bladder RMS in adults frequently demonstrates alveolar or unclassified histology, commonly with anaplasia, and have a uniformly aggressive clinical course.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Rhabdomyosarcoma, Alveolar / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anaplasia. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Combined Modality Therapy. Desmin / analysis. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Middle Aged. MyoD Protein / analysis. Myogenin / analysis. Synaptophysin / analysis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469707.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myogenin; 0 / Synaptophysin
  •  go-up   go-down


28. Donaldson SS, Meza J, Breneman JC, Crist WM, Laurie F, Qualman SJ, Wharam M, Children's Oncology Group Soft Tissue Sarcoma Committee (formely Intergroup Rhabdomyosarcoma Group) representing the Children's Oncology Group and the Quality Assurance Review Center: Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. Int J Radiat Oncol Biol Phys; 2001 Nov 1;51(3):718-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.
  • PURPOSE: To evaluate the outcome and toxicity of hyperfractionated radiotherapy (HFRT) vs. conventionally fractionated radiotherapy (CFRT) in children with Group III rhabdomyosarcoma (RMS).
  • METHODS AND MATERIALS: Five hundred fifty-nine children were enrolled into the Intergroup Rhabdomyosarcoma Study IV with Group III RMS.
  • Of the 490 remaining, 239 were randomized to HFRT (59.4 Gy in 54 1.1-Gy twice daily fractions) and 251 to CFRT (50.4 Gy in 28 1.8-Gy daily fractions).
  • All patients received chemotherapy.
  • RT began at Week 9 after induction chemotherapy for all but those with high-risk parameningeal tumors who received RT during induction chemotherapy.
  • RESULTS: Analysis by randomized treatment assignment (intent to treat) revealed an estimated 5-year failure-free survival (FFS) rate of 70% and overall survival (OS) of 75%.
  • In the univariate analysis, the factors associated with the best outcome were age 1-9 years at diagnosis; noninvasive tumors; tumor size <5 cm; uninvolved lymph nodes; Stage 1 or 2 disease; primary site in the orbit or head and neck; and embryonal histologic features (p = 0.001 for all factors).
  • No differences in the FFS or OS between the two RT treatment methods and no differences in the FFS or OS between HFRT and CFRT were found when analyzed by age, gender, tumor size, tumor invasiveness, nodal status, histologic features, stage, or primary site.
  • Treatment compliance differed by age.
  • Of the children >or=5 years, 88% assigned to both HFRT and CFRT received their assigned treatment.
  • The reasons for not receiving the appropriate randomized treatment were progressive disease, early death, parent or physician refusal, young age, or surgery.
  • The analysis by treatment actually received revealed a 5-year FFS rate of 73% and OS rate of 77%, with no difference between CFRT and HFRT.
  • The standard of care for Group III RMS continues to be CFRT with chemotherapy.
  • [MeSH-major] Dose Fractionation. Rhabdomyosarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Child. Child, Preschool. Female. Humans. Infant. Male. Patient Compliance. Radiation Injuries / classification. Radiation Injuries / pathology. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1579-80; author reply 1580 [12459396.001]
  • (PMID = 11597814.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


29. Rodriguez-Galindo C, Hill DA, Onyekwere O, Pin N, Rao BN, Hoffer FA, Kun LE, Pappo AS, Santana VM: Neonatal alveolar rhabdomyosarcoma with skin and brain metastases. Cancer; 2001 Sep 15;92(6):1613-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal alveolar rhabdomyosarcoma with skin and brain metastases.
  • RESULTS: One patient with embryonal RMS was treated successfully with a combination of systemic chemotherapy and local control measures.
  • Two of them had multiple skin and subcutaneous metastatic nodules at the time of diagnosis and developed brain metastases early in their course.
  • [MeSH-major] Brain Neoplasms / secondary. Rhabdomyosarcoma, Alveolar / pathology. Skin Neoplasms / secondary. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745240.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / PHS HHS / / LA-23099; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


30. Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ullrich F, Wharam M, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California, USA: Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group. Pediatr Blood Cancer; 2008 Jul;51(1):17-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
  • PURPOSE: Determine outcome of patients with cranial parameningeal sarcoma and concurrent metastases treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV.
  • PATIENTS: We identified 91 patients in the database, which includes newly diagnosed subjects <21 years old with rhabdomyosarcoma (RMS) and undifferentiated sarcoma, and reviewed their charts in detail.
  • RESULTS: The 54 males and 37 females were <1-19 years at diagnosis.
  • Major metastatic sites at diagnosis were lung (63%), bone marrow (33%), and bone (27%).
  • Treatment included vincristine, actinomycin D, and cyclophosphamide (VAC) chemotherapy and radiotherapy to the primary tumor and up to five metastatic sites/tissues.
  • Sixty patients had progressive disease (N = 49) or death as a first event (N = 11); another developed myelodysplastic syndrome and died.
  • Factors indicating likelihood of 10-year FFS included tumor arising in "better" versus "worse" sites (FFS 46% vs. 18%, P = 0.02) and embryonal versus other histology (FFS 37% vs. 19%, P = 0.06).
  • Patients with the best outlook had embryonal RMS located in the nasopharynx/nasal cavity, middle ear/mastoid, or parapharyngeal region.
  • Distant metastases were the most frequent type of recurrence, indicating that more effective systemic agents are needed to eliminate residual disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18266224.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


31. Missaoui N, Landolsi H, Jaidene L, Anjorin A, Abdelkader AB, Yaacoubi MT, Hmissa S: Pediatric rhabdomyosarcomas in Tunisia. Asian Pac J Cancer Prev; 2010;11(5):1325-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Rhabdomyosarcoma is the most common soft tissue sarcoma in the first two decades of life.
  • DESIGN: We retrospectively studied 30 consecutive cases of histologically proven rhabdomyosarcoma in children aged 0-15 years extracted from the database of the Cancer Registry of the Center of Tunisia for the period 1993-2007.
  • RESULTS: Rhabdomyosarcomas represented 53.6% of soft tissue sarcomas and 3.8% of all children cancer cases registered during this period.
  • The male/female ratio was 2.7 with a mean age at diagnosis of 5.9 years.
  • The embryonal subtype was the most frequent (60%) and the two most common sites of disease were the head and neck (50%) and genito-urinary tract(23.3%).
  • Chemotherapy was used in 90% of patients; 43.3% of patients had radical surgery and 26.7% of patients received radiation therapy.
  • CONCLUSION: The epidemiology, pathology and clinical features of rhabdomyosarcoma in Tunisian children are close to those reported from other countries.
  • [MeSH-major] Rhabdomyosarcoma / epidemiology. Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Head and Neck Neoplasms / therapy. Humans. Infant. Infant, Newborn. Registries. Retrospective Studies. Tunisia / epidemiology. Urologic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21198286.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


32. Malerba M, Garofalo A: [A rare case of nerve-sheath sarcoma with rhabdomyoblastic differentiation (malignant triton tumor)]. Tumori; 2003 Jul-Aug;89(4 Suppl):246-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant triton tumor (MTT) is a subtype of MPNST that also contain tissue with skeletal muscle differentiation (embryonal, plemorphic and botryoid rhabdomyosarcoma).
  • Seventeen months before, when the patient underwent surgery at the same Department for both a left-sided paravertebral inferior mediastinal neurofibroma and a right-sided axillary neurofibroma, diagnosis of von Recklinghausen disease (NF1) was made, according to the criteria established by the NIH Consensus Development.
  • The popliteal mass was resected too and resulted to be a neurofibroma just like the tumors resected 17 months before when diagnosis of von Recklinghausen disease was made.
  • Sarcoma arising in anatomic site other than extremity and superficial trunk are often more difficult to control because of anatomic constraints, delayed disease presentation, proximity to neurovascular and osseous structures and toxicity for normal adjacent tissues that limits the use of adequate radiation doses.
  • In contrast to the benefit most patients with high grade soft tissue sarcomas of the extremities receive from adjuvant radiation and chemotherapy, these modalities have been of little value for retroperitoneal tumors.
  • Current chemotherapy for retroperitoneal sarcomas is ineffective.
  • Local adjuvant therapy such as intraperitoneal chemotherapy or experimental immunotherapy seems to be attractive in theory, but needs further investigations through prospective randomized multicentric trials.
  • In conclusion, to date aggressive surgical management remains the most effective modality for selected primary and recurrent retroperitoneal soft tissue sarcomas including MPNSTs and the subtype MTT.
  • Patients with incomplete resection and other risk factors such as younger age and high grade tumors may be suitable candidates for investigational adjuvant therapy.
  • [MeSH-minor] Adult. Axilla. Cell Differentiation. Humans. Knee. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Muscles / pathology. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Spinal Nerve Roots / pathology. Spinal Nerve Roots / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12903608.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Alaggio R, Ninfo V, Rosolen A, Coffin CM: Primitive myxoid mesenchymal tumor of infancy: a clinicopathologic report of 6 cases. Am J Surg Pathol; 2006 Mar;30(3):388-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue sarcomas in the first year of life are rare, and the most common sarcomas in infancy are embryonal rhabdomyosarcoma, Ewing sarcoma/primitive neuroectodermal tumor, congenital infantile fibrosarcoma, and primitive sarcomas such as undifferentiated sarcoma.
  • PMMTI occurred in 6 infants, 3 of whom had a congenital presentation of a soft tissue mass.
  • Three patients had recurrences or metastasis treated with a combination of surgery and chemotherapy.
  • One patient is alive with persistent locally aggressive disease, 2 are alive with no evidence of recurrence, 1 had a recurrence treated surgically without further follow-up information, 1 patient died with persistent tumor and sepsis 6 weeks after diagnosis, and 1 patient was lost to follow-up.
  • [MeSH-major] Fibrosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Dermatofibrosarcoma / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Microscopy, Electron, Transmission. Neoplasm Recurrence, Local / pathology. Nerve Sheath Neoplasms / pathology. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538060.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ETV6-NTRK3 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


34. Kebudi R, Ayan I, Görgün O, Ağaoğlu FY, Vural S, Darendeliler E: Brain metastasis in pediatric extracranial solid tumors: survey and literature review. J Neurooncol; 2005 Jan;71(1):43-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to investigate the incidence, treatment, prognosis of brain metastasis in extracranial pediatric malignant tumors in a single institution and to review the literature.
  • RESULTS: Sixteen (10 female, 6 male) of 1100 patients (1.45%) with extracranial solid tumors developed brain metastases.
  • The diagnosis was sarcomas in 12 patients: 5 osteosarcomas, 4 Ewing's sarcoma family tumors, 1 rhabdomyosarcoma, 1 clear cell sarcoma of the soft tissue, 1 alveolar soft part sarcoma.
  • Four patients (25%) had brain metastasis at diagnosis.
  • Twelve (75%) developed brain metastasis during therapy or relapse at a median duration of 16 (1-70) months from initial diagnosis.
  • All patients had metastases to various sites, mostly lung, at the time the brain metastases were detected.
  • Treatment included surgery, followed by postoperative radiotherapy (RT) and chemotherapy (CT) in 1, S and RT in 1, S in 1, RT and CT in 6, RT in 1, CT in 1 and no treatment in 5.
  • Only one patient with alveolar soft part sarcoma is alive with disease 20 months from diagnosis of brain metastasis.
  • All other patients died at a median time of 2 months (2 days-6 months) from the time of brain metastasis.
  • Although, the outcome for these patients is dismal in this series and in the literature; reports of long term survival in a few cases with Wilms' tumor, osteosarcoma and alveolar soft part sarcoma who had isolated brain metastasis, suggest that a subset of patients may benefit from therapy.
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Bone Neoplasms / epidemiology. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Child. Child, Preschool. Female. Humans. Infant. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Mediastinal Neoplasms / epidemiology. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / therapy. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Wilms Tumor / epidemiology. Wilms Tumor / secondary. Wilms Tumor / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Feb 1;61(3):593-601 [3276383.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2160-4 [6593114.001]
  • [Cites] Oncology. 1995 Mar-Apr;52(2):89-92 [7854781.001]
  • [Cites] Arch Neurol. 1988 Jul;45(7):741-4 [3390029.001]
  • [Cites] Neurosurg Rev. 1990;13(3):247-52 [1697937.001]
  • [Cites] Eur J Nucl Med. 1983;8(12 ):552-4 [6230234.001]
  • [Cites] Pediatr Neurol. 2002 Mar;26(3):219-21 [11955930.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Nov-Dec;16(6):545-9 [10599095.001]
  • [Cites] J Neurooncol. 1988;6(1):47-52 [3165112.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3656-60 [8490913.001]
  • [Cites] Cancer. 1982 Jun 1;49(11):2404-9 [7074552.001]
  • [Cites] J Pediatr. 1983 Oct;103(4):558-61 [6620015.001]
  • [Cites] Neurology. 1974 Oct;24(10):981-5 [4369837.001]
  • [Cites] J Korean Med Sci. 1997 Oct;12(5):473-6 [9364310.001]
  • [Cites] Indian J Cancer. 1997 Mar;34(1):26-9 [9491660.001]
  • [Cites] Lancet Oncol. 2002 Aug;3(8):498-507 [12147436.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):2023-9 [9806663.001]
  • [Cites] Med Pediatr Oncol. 2002 Jul;39(1):60-2 [12116085.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):377-80 [6243247.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Nov;34(11):754-8 [7533270.001]
  • [Cites] Neurology. 1998 Nov;51(5):1336-8 [9818856.001]
  • [Cites] Neurosurgery. 1979 Jul;5(1 Pt 1):44-8 [471204.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 3:iii4-10 [12821532.001]
  • [Cites] Cancer. 1979 Feb;43(2):707-10 [283879.001]
  • [Cites] Neurosurgery. 1994 Aug;35(2):185-90; discussion 190-1 [7969824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Aug;8(8):1441-6 [7141922.001]
  • [Cites] Jpn J Clin Oncol. 1999 May;29(5):245-7 [10379335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):177-83 [12909231.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Sep-Oct;21(5):370-7 [10524449.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):403-10 [9010115.001]
  • [Cites] Acta Neuropathol. 1985;67(3-4):341-4 [4050350.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):149-55 [1734220.001]
  • [Cites] Surg Neurol. 1998 Apr;49(4):441-4 [9537665.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):699-702 [3838542.001]
  • [Cites] Pediatr Neurosurg. 1999 Jun;30(6):331-4 [10494060.001]
  • [Cites] Childs Nerv Syst. 1998 Dec;14(12):713-8 [9881624.001]
  • [Cites] Surg Neurol. 1989 Mar;31(3):234-8 [2922669.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1203-8 [8339211.001]
  • [Cites] Acta Neurol Belg. 1990;90(3):149-56 [2120904.001]
  • [Cites] J Pediatr Surg. 1995 Nov;30(11):1607-8 [8583337.001]
  • (PMID = 15719274.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 43
  •  go-up   go-down






Advertisement